Sorrento Therapeutics, Inc. – Amended and Restated Loan and Security Agreement (April 1st, 2014)
THIS AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT (as the same may from time to time be amended, modified, supplemented or restated, this Agreement) dated as of March 31, 2014 (the Effective Date) among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 133 North Fairfax Street, Alexandria, Virginia 22314 (Oxford), as collateral agent (in such capacity, Collateral Agent), the Lenders listed on Schedule 1.1 hereof or otherwise a party hereto from time to time including Oxford in its capacity as a Lender and SILICON VALLEY BANK, a California corporation with an office located at 3003 Tasman Drive, Santa Clara, CA 95054 (Bank or SVB) (each a Lender and collectively, the Lenders), and SORRENTO THERAPEUTICS, INC., a Delaware corporation (Parent), IGDRASOL, INC., a Delaware corporation (IgDraSol), and SHERRINGTON PHARMACEUTICALS, INC., a Delaware corporation (Sherrington), each with offices located at 6042 Cornerstone Court, Suite B, San Diego, CA 92121, C
Sorrento Therapeutics, Inc. – Agreement and Plan of Merger (September 11th, 2013)
THIS AGREEMENT AND PLAN OF MERGER (Agreement) is made and entered into as of September 9, 2013, by and among: Sorrento Therapeutics, Inc., a Delaware corporation (Parent); STI Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (Merger Sub); IgDraSol, Inc., a Delaware corporation (the Company); Vuong Trieu as the Stockholders Agent and all the stockholders of the Company (each a Stockholder). Certain other capitalized terms used in this Agreement are defined in Exhibit A.
Sorrento Therapeutics, Inc. – Voting Agreement (May 15th, 2013)
THIS VOTING AGREEMENT (Voting Agreement) is entered into as of March 7, 2013, by and among SORRENTO THERAPEUTICS, INC., a Delaware corporation (Sorrento), IGDRASOL, INC., a Delaware corporation (the IgDraSol) and the stockholder signatories hereto (Stockholder).